CAMP4 Reports Third Quarter 2024 Financial Results


- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered strategic research collaboration with BioMarin valued at over $370M

Read the rest here:
CAMP4 Reports Third Quarter 2024 Financial Results

Related Posts